How should I manage a urine culture that isolates Morganella morganii subsp. morganii at >100,000 CFU/mL (significant) and a second Gram‑negative bacillus at <10,000 CFU/mL (likely contaminant)?

Management of Polymicrobial Urine Culture with Morganella morganii

Treat the Morganella morganii (>100,000 CFU/mL) as a true pathogen and disregard the second organism at <10,000 CFU/mL as contamination. The second organism does not meet diagnostic thresholds for urinary tract infection and should not influence your antimicrobial selection.

Interpretation of Culture Results

The culture shows:

• Morganella morganii at >100,000 CFU/mL: This meets the diagnostic threshold (≥10⁵ CFU/mL) for true bacteriuria 1
• Second gram-negative bacillus at <10,000 CFU/mL: This falls well below the diagnostic threshold and represents either contamination or colonization from urethral/perineal flora 1, 2

Key principle: Urine samples with mixed growth where one organism is at significantly lower counts should have the low-count organism disregarded 3. The laboratory's notation that the second organism "may be of questionable significance" correctly identifies this as likely contamination.

Clinical Context Assessment

Before treating, determine if this represents:

1. Symptomatic UTI (cystitis or pyelonephritis): Fever, dysuria, urgency, frequency, flank pain, or suprapubic tenderness
2. Asymptomatic bacteriuria (ASB): Positive culture without UTI symptoms

If asymptomatic, do NOT treat unless the patient is pregnant or undergoing invasive urologic procedures with expected mucosal bleeding 4, 1. Unnecessary treatment of ASB increases antimicrobial resistance without clinical benefit.

Antimicrobial Selection for Morganella morganii

Morganella morganii has intrinsic resistance to:

• Amoxicillin-clavulanate (uniformly resistant) 5
• Nitrofurantoin (uniformly resistant) 5
• First- and second-generation cephalosporins 6

Preferred agents based on susceptibility data:

• Aminoglycosides (amikacin, gentamicin): Uniformly sensitive 5, 7
• Cefepime (4th-generation cephalosporin): Uniformly sensitive 5
• Piperacillin-tazobactam: Uniformly sensitive 5
• Carbapenems (imipenem, meropenem): High susceptibility 7
• Ceftazidime (3rd-generation): Generally susceptible 7

Common pitfall: Do not use amoxicillin-clavulanate or nitrofurantoin empirically for Morganella—these will fail 5.

Treatment Duration

For symptomatic cystitis: 5-7 days of appropriate antimicrobial therapy 4

For pyelonephritis or febrile UTI:

• Fluoroquinolones: 5-7 days
• Dose-optimized β-lactams: 7 days 4

For gram-negative bacteremia from urinary source: 7 days total when source control is achieved 4

Special Populations

High-risk patients for Morganella infection 5, 8:

• Neurogenic bladder or urinary catheter use
• Urological abnormalities (myelomeningocele)
• Elderly patients (>65 years)
• ICU patients
• Immunocompromised hosts

These patients warrant more aggressive treatment and closer monitoring, as Morganella bacteremia carries 41% in-hospital mortality in high-risk populations 8.

Practical Approach

1. Assess symptoms: If asymptomatic (except pregnancy/pre-urologic procedure), do not treat
2. Review local antibiogram: Verify susceptibilities for your specific isolate
3. Select appropriate agent: Avoid amoxicillin-clavulanate and nitrofurantoin; prefer aminoglycosides, cefepime, or piperacillin-tazobactam
4. Treat for 5-7 days (uncomplicated) or 7 days (complicated/pyelonephritis)
5. Ignore the second organism: It does not meet diagnostic criteria and should not influence management

Critical caveat: If the patient has recurrent UTIs or treatment failure, consider underlying urological abnormalities that may require imaging or urologic evaluation, as Morganella is associated with structural abnormalities 5.